Eli Lilly (LLY) Q4 and Annual 2025 Earnings
Eli Lilly reported Q4 2025 revenue of $19.3B (+42.6% YoY), beat analyst consensus of $17.9B by $1.3B. Diluted EPS came in at $7.54 (+41.7% YoY), beat the $6.91 consensus by $0.63. Eli Lilly reports across 4 business segments, led by Cardiometabolic Health, Oncology, and Immunology.
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Eli Lilly's Q4 2025 earnings report.
Eli Lilly (LLY) reported Q4 2025 earnings on February 4, 2026 before market open.
Eli Lilly reported revenue of $19.3B and diluted EPS of $7.54 for Q4 2025.
Revenue beat the consensus estimate of $17.9B by $1.3B. EPS beat the consensus estimate of $6.91 by $0.63.
Compared to the same quarter a year prior, revenue grew 42.6% from $13.5B a year earlier and diluted EPS grew 41.7% from $5.32.
Eli Lilly reports across 4 business segments, led by Cardiometabolic Health, Oncology, and Immunology. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0000059478-26-000008) and the 10-K periodic report (0000059478-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.